June 29, 2020 / 7:34 AM / 4 days ago

BRIEF-Pharma Mar Receives Payment Of 100 Mln Dollars From Jazz Pharmaceuticals For Lurbinectedin US Approval

June 29 (Reuters) - Pharma Mar SA:

* RECEIVES PAYMENT OF 100 MILLION DOLLARS FROM JAZZ PHARMACEUTICALS FOR APPROVAL OF LURBINECTEDIN IN U.S. AS TREATMENT FOR METASTATIC SMALL CELL LUNG CANCER​

* MAY RECEIVE UP TO AN ADDITIONAL 150 MILLION EUROS ADDITIONAL ONCE “FULL APPROVAL” OCCURS

* COMMERCIAL LAUNCH OF LURBINECTEDIN (ZEPZELCA) IN U.S. TO START IN JULY BY JAZZ PHARMACEUTICALS

* MAY RECEIVE UP TO AN ADDITIONAL 550 MILLION DOLLARS FOR BUSINESS OBJECTIVES Source text: bit.ly/3ieSQFl Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below